Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
504-04-002 ISMRM Abstract

Integrated Metabolic and Imaging Assessment of mTOR Inhibition by Torin2 in Diffuse Large B-Cell Lymphoma

Primary: Preclinical Animal & in vitro MR - Biomarkers
Secondary: Transferable Skills
504-04-002 · Cancer Imaging and Spectroscopy · Wednesday, 13 May, 4:00 PM–5:50 PM · Ballroom East
Keywords: In vivo proton magnetic resonance spectroscopy Therapeutic response MTOR inhibition Metabolic reprogramming Diffuse large B-cell lymphoma (DLBCL)
Accepted
Pradeep Kumar Gupta 1, Shengchun Wang2, Mamta Gupta1, Shilpa Rao2, Aria Osborne1, David Rushmore2, David Nelson1, Johnvesly Basappa2, Mariusz A Wasik2, Kavindra Nath1
1University of Pennsylvania, Philadelphia, United States of America
2Department of Pathology, Fox Chase Cancer Center, Philadelphia, United States of America
Presenting Author: Pradeep Kumar Gupta

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. 1. Bakhshi TJ, Georgel PT. Genetic and epigenetic determinants of diffuse large B-cell lymphoma. Blood Cancer Journal. 2020;10(12):123. doi: 10.1038/s41408-020-00389-w. [doi]
2. 2. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274-93. doi: 10.1016/j.cell.2012.03.017. PubMed PMID: 22500797; PMCID: PMC3331679. [doi] [pmid]
3. 3. Simioni C, Cani A, Martelli AM, Zauli G, Tabellini G, McCubrey J, Capitani S, Neri LM. Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation. Oncotarget. 2014;5(20):10034-47. doi: 10.18632/oncotarget.2490. PubMed PMID: 25296981; PMCID: PMC4259403. [doi] [pmid]
4. 4. Argyriou P, Economopoulou P, Papageorgiou S. The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas. Adv Hematol. 2012;2012:435342. Epub 20110616. doi: 10.1155/2012/435342. PubMed PMID: 21822434; PMCID: PMC3124126. [doi] [pmid]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/504-04-002